普拉曲沙是一种新型抗叶酸药物，对还原型叶酸载体1型具有高亲和力，在多种化疗难治性T细胞淋巴瘤病例中可产生显著的完全缓解且缓解持久。

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.

作者信息

O'Connor Owen A, Hamlin Paul A, Portlock Carol, Moskowitz Craig H, Noy Ariela, Straus David J, Macgregor-Cortelli Barbara, Neylon Ellen, Sarasohn Debra, Dumetrescu Otila, Mould Diane R, Fleischer Martin, Zelenetz Andrew D, Sirotnak Frank, Horwitz Steven

机构信息

Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA.

出版信息

Br J Haematol. 2007 Nov;139(3):425-8. doi: 10.1111/j.1365-2141.2007.06658.x.

DOI:10.1111/j.1365-2141.2007.06658.x

PMID:17910632

Abstract

T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B-cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B-cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.

摘要

T细胞淋巴瘤（TCLs）的特点是对治疗反应不佳，缓解期短暂。普拉曲沙的一项早期研究表明，其对复发/难治性疾病患者具有显著活性。在最初接受治疗的20例淋巴瘤患者中，16例为B细胞淋巴瘤，4例为难治性侵袭性TCL。所有4例TCL患者均实现完全缓解。B细胞淋巴瘤患者至多达到疾病稳定。对于每例TCL患者，其反应比化疗时的最佳反应更持久。这一早期经验首次记录了普拉曲沙在TCL中的这种独特活性。